{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:32:28Z","timestamp":1792726348697,"version":"4.5.0"},"reference-count":46,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Anbalcabtagene autoleucel (anbal-cel) is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy incorporating dual PD-1 and TIGIT knockdown to enhance antitumor function and durability. We report results from a phase 1 and 2 study in patients with relapsed or refractory large B-cell lymphoma. In phase 2, 79 patients received anbal-cel, and its efficacy was evaluated in 73 patients. The complete response (CR) and partial response rates were 67.1% and 8.2%, respectively. Median progression-free survival (PFS) was 6.04 months (95% confidence interval, 4.34-16.46), and the 6-, 12-, and 18-month PFS rates were 50.9%, 41.1%, and 35.2%, respectively. Median overall survival (OS) was not reached, with 12- and 18-month OS rates of 66.6% and 57.3%, respectively. CAR T-cell expansion (Cmax) was significantly greater in responders than in nonresponders (median Cmax, 20\u2009403 vs 8580 copies per \u03bcg). Patients were categorized into long-term response (LR) group or non-LR group based on sustained CR at 6 months. Reduced PD-1 and TIGIT expression on CAR+ T cells was observed in the LR group. Most patients (97.5%) experienced grade \u22653 adverse events, most commonly neutropenia (93.7%), followed by thrombocytopenia (41.8%) and anemia (30.4%). Cytokine release syndrome (CRS) and neurological events occurred in 57.0% and 13.9% of patients, respectively. Grade 3 CRS occurred in 8.9% of patients, with no grade 4 events reported, and grade \u22653 neurological events occurred in 3.8% of patients. Serious infections occurred in 25.3% of patients, including grade 5 infection reported in 3 patients. This trial was registered at www.clinicaltrials.gov as #NCT04836507.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032636","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:56:08Z","timestamp":1781283368000},"page":"2132-2145","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Anbalcabtagene autoleucel (PD-1 and TIGIT knockdown CD19 CAR T-cell therapy) for relapsed or refractory LBCL: the CRC01-01 trial"],"prefix":"10.1182","volume":"148","author":[{"given":"Won Seog","family":"Kim","sequence":"first","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2776-4401","authenticated-orcid":false,"given":"Seok Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dok Hyun","family":"Yoon","sequence":"additional","affiliation":[{"name":"2Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4307-2795","authenticated-orcid":false,"given":"Hyungwoo","family":"Cho","sequence":"additional","affiliation":[{"name":"2Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[{"name":"1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deok Hwan","family":"Yang","sequence":"additional","affiliation":[{"name":"3Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-jin","family":"Shin","sequence":"additional","affiliation":[{"name":"4Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-2067","authenticated-orcid":false,"given":"Hyeon-Seok","family":"Eom","sequence":"additional","affiliation":[{"name":"5Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunyoung","family":"Lee","sequence":"additional","affiliation":[{"name":"5Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-5553","authenticated-orcid":false,"given":"Ja Min","family":"Byun","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-931X","authenticated-orcid":false,"given":"Youngil","family":"Koh","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9562-4101","authenticated-orcid":false,"given":"Hyewon","family":"Lee","sequence":"additional","affiliation":[{"name":"5Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5886-0933","authenticated-orcid":false,"given":"Jongheon","family":"Jung","sequence":"additional","affiliation":[{"name":"5Department of Hematology-Oncology, Center for Hematologic Malignancy, National Cancer Center, Goyang, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-7459","authenticated-orcid":false,"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga-Young","family":"Song","sequence":"additional","affiliation":[{"name":"3Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9468-8939","authenticated-orcid":false,"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[{"name":"4Division of Hematology-Oncology, Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine, Busan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyeon","family":"Hong","sequence":"additional","affiliation":[{"name":"7Chemical and Biological Integrative Research Center, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-8901","authenticated-orcid":false,"given":"Yoon","family":"Park","sequence":"additional","affiliation":[{"name":"7Chemical and Biological Integrative Research Center, Biomedical Research Institute, Korea Institute of Science and Technology, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhee","family":"Han","sequence":"additional","affiliation":[{"name":"8Curocell Inc, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0616-5880","authenticated-orcid":false,"given":"Su-Hee","family":"Cho","sequence":"additional","affiliation":[{"name":"8Curocell Inc, Daejeon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"47","key":"2026102211215837700_bib1","first-page":"277","article-title":"Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells","volume":"9","author":"Park","year":"2010","journal-title":"Discov Med"},{"issue":"16","key":"2026102211215837700_bib2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"2026102211215837700_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"37","key":"2026102211215837700_bib4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging cellular therapies for cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2026102211215837700_bib5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"2026102211215837700_bib6","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"26","key":"2026102211215837700_bib7","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2026102211215837700_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10254","key":"2026102211215837700_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"2026102211215837700_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2018.08.002","article-title":"Checkpoint blockade reverses anergy in IL-13R\u03b12 humanized scFv-based CAR T cells to treat murine and canine gliomas","volume":"11","author":"Yin","year":"2018","journal-title":"Mol Ther Oncolytics"},{"issue":"4","key":"2026102211215837700_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"issue":"14","key":"2026102211215837700_bib12","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1080\/10428194.2023.2258244","article-title":"Functional drivers of resistance to anti-CD19 CAR-T cell therapy in diffuse large B cell lymphoma","volume":"64","author":"Newsam","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2026102211215837700_bib13","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2026102211215837700_bib14","doi-asserted-by":"crossref","first-page":"210-225.e5","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2023","journal-title":"Cancer Cell"},{"key":"2026102211215837700_bib15","doi-asserted-by":"crossref","first-page":"1399544","DOI":"10.3389\/fonc.2024.1399544","article-title":"Challenges and innovations in CAR-T cell therapy: a comprehensive analysis","volume":"14","author":"Luo","year":"2024","journal-title":"Front Oncol"},{"issue":"8","key":"2026102211215837700_bib16","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1016\/j.apsb.2024.04.022","article-title":"Unlocking T cell exhaustion: insights and implications for CAR-T cell therapy","volume":"14","author":"Xiong","year":"2024","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"2026102211215837700_bib17","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"8","key":"2026102211215837700_bib18","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"issue":"8","key":"2026102211215837700_bib19","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)\u2013modified T cells: refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"issue":"3","key":"2026102211215837700_bib20","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/2326-6066.CIR-18-0351","article-title":"TIGIT and PD-1 mark intratumoral T cells with reduced effector function in B-cell non-Hodgkin lymphoma","volume":"7","author":"Josefsson","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"2026102211215837700_bib21","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2026102211215837700_bib22","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","article-title":"PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells","volume":"30","author":"Lee","year":"2022","journal-title":"Mol Ther"},{"issue":"27","key":"2026102211215837700_bib23","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026102211215837700_bib24","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","article-title":"Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study","volume":"107","author":"Kostakoglu","year":"2022","journal-title":"Haematologica"},{"issue":"4","key":"2026102211215837700_bib25","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2026102211215837700_bib26","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jfma.2021.10.020","article-title":"Optic neuropathy after chimeric antigen receptor T-cell therapy","volume":"121","author":"Huang","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"7","key":"2026102211215837700_bib27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/bjophthalmol-2021-320814","article-title":"Ocular adverse events associated with chimeric antigen receptor T-cell therapy: a case series and review","volume":"107","author":"Mumtaz","year":"2023","journal-title":"Br J Ophthalmol"},{"key":"2026102211215837700_bib28","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3389\/fonc.2019.00767","article-title":"Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"9","author":"Cao","year":"2019","journal-title":"Front Oncol"},{"issue":"1","key":"2026102211215837700_bib29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"19","key":"2026102211215837700_bib30","doi-asserted-by":"crossref","first-page":"14780","DOI":"10.3390\/ijms241914780","article-title":"Combined or sequential treatment with immune checkpoint inhibitors and CAR-T cell therapies for the management of haematological malignancies: a systematic review","volume":"24","author":"P\u00e9rez-Moreno","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2026102211215837700_bib31","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4143\/crt.2025.276","article-title":"Comparative effectiveness of anbalcabtagene autoleucel versus tisagenlecleucel in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"58","author":"Seo","year":"2025","journal-title":"Cancer Res Treat"},{"issue":"14","key":"2026102211215837700_bib32","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N Engl J Med"},{"issue":"1","key":"2026102211215837700_bib33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","article-title":"Implications of high tumor burden on chimeric antigen receptor T-cell immunotherapy: a review","volume":"10","author":"Ventin","year":"2024","journal-title":"JAMA Oncol"},{"issue":"5","key":"2026102211215837700_bib34","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"2026102211215837700_bib35","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1158\/1078-0432.CCR-22-0164","article-title":"Phenotypic composition of commercial anti-CD19 CAR T cells affects in vivo expansion and disease response in patients with large B-cell lymphoma","volume":"28","author":"Monfrini","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2026102211215837700_bib36","first-page":"4832","article-title":"NFATc1 regulates programmed death-1 expression upon T cell activation","volume":"181","author":"Oestreich","year":"2008","journal-title":"J Immunol 1950"},{"issue":"7764","key":"2026102211215837700_bib37","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"7764","key":"2026102211215837700_bib38","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-019-1326-9","article-title":"TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection","volume":"571","author":"Alfei","year":"2019","journal-title":"Nature"},{"issue":"1","key":"2026102211215837700_bib39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","article-title":"Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies","volume":"40","author":"Xiao","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"2026102211215837700_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2026102211215837700_bib41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026102211215837700_bib42","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal hematopoiesis to secondary leukemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"suppl 1","key":"2026102211215837700_bib43","first-page":"S214","article-title":"Phase 1\/2 study of anbal-cel, novel anti-CD19 CAR-T therapy with dual silencing of PD-1 and TIGIT in relapsed or refractory large B-cell lymphoma","volume":"6","author":"Kim","year":"2022","journal-title":"HemaSphere"},{"key":"2026102211215837700_bib44","author":"Kim","year":"15  2023"},{"issue":"suppl 1","key":"2026102211215837700_bib45","first-page":"1165","article-title":"Anbalcabtagene autoleucel (PD-1 and TIGIT knock-downed CD19 CAR-T) for relapsed or refractory large B-cell lymphoma patients: result of a pivotal phase 2 study","volume":"8","author":"Kim","year":"2024","journal-title":"HemaSphere"},{"key":"2026102211215837700_bib46","author":"Kim","year":"17-21  2025"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025032636\/2595440\/blood_bld-2025-032636-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/doi\/10.1182\/blood.2025032636\/2595440\/blood_bld-2025-032636-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:22:06Z","timestamp":1792682526000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/17\/2132\/569111\/Anbalcabtagene-autoleucel-PD-1-and-TIGIT-knockdown"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":46,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032636","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,22]]},"published":{"date-parts":[[2026,10,22]]}}}